Compounding Record compoundingrecord.com

Warning-Letter Pattern Library

FDA warning-letter patterns

Enforcement signals extracted from sampled FDA warning letters. This view is source-backed but remains internal until human review clears each takeaway.

Publication status

Internal

2 letters queued for human review

Generated

Apr 30, 2026, 7:52 PM UTC

All visible claims require fact support.

2 warning letters sampled
6 pattern categories observed
6 distinct violations extracted
2 letters pending review

Pattern Counts

Counts come from sampled letters only. They are not an exhaustive FDA enforcement taxonomy.

  1. False Or Misleading Claims 2
  2. Implied FDA Approval Or Evaluation 2
  3. Adequate Directions For Use 1
  4. Implied Compounder Identity 1
  5. Non Bulks List Substance 1
  6. Unapproved New Drug 1

FDA warning letters objected to compounded GLP-1 marketing claims that compare compounded products to branded drugs using same-active-ingredient language.

Support2 references

Fact IDs

Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:09 PM UTC
Effective
Feb 20, 2026

Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®) | Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)

fact:29be2cb4-03d8-4a14-9207-f63a54656013Source
Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:12 PM UTC
Effective
Sep 9, 2025

Compounded Retatrutide [--] Active Ingredient in Mounjaro and Zepbound | Compounded Retatrutide [--] Active Ingredient in Ozempic and Wegovy | Doctors frequently recommend Compounded Tirzepatide (Mounjaro/Zepbound) or Compounded Semaglutide (Wegovy, Ozempic), which are both GLP-1 agonists.

fact:ead9368d-e6ce-4a39-a494-2ce283ca4b49Source

FDA treated claims implying compounded products were FDA-approved or FDA-evaluated as false or misleading.

Support2 references

Fact IDs

Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:09 PM UTC
Effective
Feb 20, 2026

Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®) | Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)

fact:29be2cb4-03d8-4a14-9207-f63a54656013Source
Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:12 PM UTC
Effective
Sep 9, 2025

Compounded Retatrutide [--] Active Ingredient in Mounjaro and Zepbound | Compounded Retatrutide [--] Active Ingredient in Ozempic and Wegovy | Doctors frequently recommend Compounded Tirzepatide (Mounjaro/Zepbound) or Compounded Semaglutide (Wegovy, Ozempic), which are both GLP-1 agonists.

fact:ead9368d-e6ce-4a39-a494-2ce283ca4b49Source

FDA objected when website labeling suggested a telehealth brand was the compounder of products when it was not.

Support1 reference

Fact IDs

Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:09 PM UTC
Effective
Feb 20, 2026

Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®) | Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)

fact:29be2cb4-03d8-4a14-9207-f63a54656013Source

FDA cited retatrutide products as failing to meet 503A and 503B conditions because retatrutide did not appear on the relevant bulks lists.

Support1 reference

Fact IDs

Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:12 PM UTC
Effective
Sep 9, 2025

Compounded Retatrutide [--] Active Ingredient in Mounjaro and Zepbound | Compounded Retatrutide [--] Active Ingredient in Ozempic and Wegovy | Doctors frequently recommend Compounded Tirzepatide (Mounjaro/Zepbound) or Compounded Semaglutide (Wegovy, Ozempic), which are both GLP-1 agonists.

fact:ead9368d-e6ce-4a39-a494-2ce283ca4b49Source

Sampled Letters

Quoted claims are short FDA-cited excerpts. Display with source context before publication.

BluefitMD

compounded GLP-1 · Feb 20, 2026

Queued
MARCS-CMS
721446
Confidence
95%
Website
https://www.bluefitmd.com/
Source fact1 reference

Fact IDs

Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:09 PM UTC
Effective
Feb 20, 2026

Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®) | Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)

fact:29be2cb4-03d8-4a14-9207-f63a54656013Source

Quoted claims

  • Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®)
  • Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)

Violation tags

False Or Misleading ClaimsImplied Compounder IdentityImplied FDA Approval Or Evaluation

Statutes cited

502(a)502(bb)301(a)301(c)503A503B

GenLabMeds

compounded GLP-1 / retatrutide · Sep 9, 2025

Queued
MARCS-CMS
713650
Confidence
95%
Website
https://genlabmeds.com
Source fact1 reference

Fact IDs

Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:12 PM UTC
Effective
Sep 9, 2025

Compounded Retatrutide [--] Active Ingredient in Mounjaro and Zepbound | Compounded Retatrutide [--] Active Ingredient in Ozempic and Wegovy | Doctors frequently recommend Compounded Tirzepatide (Mounjaro/Zepbound) or Compounded Semaglutide (Wegovy, Ozempic), which are both GLP-1 agonists.

fact:ead9368d-e6ce-4a39-a494-2ce283ca4b49Source

Quoted claims

  • Compounded Retatrutide [--] Active Ingredient in Mounjaro and Zepbound
  • Compounded Retatrutide [--] Active Ingredient in Ozempic and Wegovy
  • Doctors frequently recommend Compounded Tirzepatide (Mounjaro/Zepbound) or Compounded Semaglutide (Wegovy, Ozempic), which are both GLP-1 agonists.

Violation tags

False Or Misleading ClaimsImplied FDA Approval Or EvaluationNon Bulks List SubstanceUnapproved New DrugAdequate Directions For Use

Statutes cited

505(a)502(f)(1)301(a)301(d)502(a)502(bb)503A503B

Publication Caveats

Caveats are rendered as first-class claims because they are part of the trust posture.

The extracted warning-letter patterns are examples from sampled FDA letters, not an exhaustive enforcement taxonomy.

Support2 references

Fact IDs

Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:09 PM UTC
Effective
Feb 20, 2026

Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®) | Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)

fact:29be2cb4-03d8-4a14-9207-f63a54656013Source
Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:12 PM UTC
Effective
Sep 9, 2025

Compounded Retatrutide [--] Active Ingredient in Mounjaro and Zepbound | Compounded Retatrutide [--] Active Ingredient in Ozempic and Wegovy | Doctors frequently recommend Compounded Tirzepatide (Mounjaro/Zepbound) or Compounded Semaglutide (Wegovy, Ozempic), which are both GLP-1 agonists.

fact:ead9368d-e6ce-4a39-a494-2ce283ca4b49Source

Warning-letter takeaways require human review before publication because they can be read as legal or operational guidance.

Support2 references

Fact IDs

Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:09 PM UTC
Effective
Feb 20, 2026

Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®) | Compounded Tirzepatide (the same active ingredient as Mounjaro® & Zepbound®)

fact:29be2cb4-03d8-4a14-9207-f63a54656013Source
Warning LetterVerified
Confidence
95%
Review
Queued
Source
FDA HTML
Verified
Apr 30, 2026, 7:12 PM UTC
Effective
Sep 9, 2025

Compounded Retatrutide [--] Active Ingredient in Mounjaro and Zepbound | Compounded Retatrutide [--] Active Ingredient in Ozempic and Wegovy | Doctors frequently recommend Compounded Tirzepatide (Mounjaro/Zepbound) or Compounded Semaglutide (Wegovy, Ozempic), which are both GLP-1 agonists.

fact:ead9368d-e6ce-4a39-a494-2ce283ca4b49Source

Review Notes

Warning-letter pattern extraction is source-backed but requires human review before publication.
Quoted claims are short FDA-cited excerpts and should be displayed with source links and context.